Article citationsMore>>

Necchi, A., Mariani, L., Zaffaroni, N., Schwartz, L.H., Giannatempo, P., Crippa, F., et al. (2012) Pazopanib in Advanced and Platinum-Resistant Urothelial Cancer: An Open-Label, Single Group, Phase 2 Trial. The Lancet Oncology, 13, 810-816.
https://doi.org/10.1016/s1470-2045(12)70294-2

has been cited by the following article:

• TITLE: Urine-Based Liquid Biopsy for Detecting Recurrence of Bladder Cancer

  AUTHORS: Wanting Xu, Xing Xing, Shaoping Cheng

  KEYWORDS: Bladder Cancer, Recurrence, Urine, Biomarkers

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.16 No.12, December 9, 2025

  ABSTRACT: Bladder cancer represents a widespread malignant neoplasm globally, characterized by a notable rate of recurrence following the initial diagnosis and treatment. Traditional methods for identifying and monitoring the recurrence of bladder cancer include cystoscopy and cytological assessments. Nonetheless, the invasive nature of cystoscopy and the restricted sensitivity of urinary cytology in identifying low-grade tumors pose significant challenges. Presently, there is a deficiency of reliable biomarkers for the early detection and prognostic evaluation of bladder cancer. Urine serves as a rich reservoir of tumor-associated proteins, DNA, and RNA, which holds considerable clinical significance for detection purposes. However, the sensitivity and specificity of various biomarkers necessitate further validation. With advancements in detection methodologies and precision medicine, urinary biomarkers are anticipated to assume an increasingly crucial role in the clinical diagnosis and monitoring of bladder cancer recurrence.